GLP-1s enhance blood sugar control and other metabolic markers by stimulating the release of insulin, a hormone that regulates blood sugar, while suppressing the secretion of glucagon, a hormone that raises blood sugar
According to incomplete statistics, sales of Novo Nordisk's semaglutide have been soaring year after year, with 2023 sales surpassing $21.2 billion, making it the first GLP-1 drug to join the "billion-dollar club." Its market position is quickly catching up with Merck's Keytruda, and it has the potential to become the next "blockbuster" drug
Fast, effective weight loss Achieve better skin Lower blood sugar and blood pressure Prevent cardiovascular diseases Strengthen the digestive system Natural ingredients, no side effects Suitable for people of all ages Block fat absorption, cleanse the liver No dieting required, no rebound Relieve pain and swelling Reduce stress and anxiety Boost energy and vitality Developed and manufactured in MHRA-registered laboratories in the UK FAQ 1
Por estimular el efecto de las endorfinas